Last reviewed · How we verify
NCT06911060
The Effect of Flaxseed Consumption on Biochemical Parameters and Quality of Life in Patients With Type 2 Diabetes
NA trial testing Flaxseed in Type 2 Diabetes Mellitus (T2DM) in 46 participants. Not yet recruiting.
1 April 2026
Quick facts
| Lead sponsor | Ondokuz Mayıs University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 46 |
| Start date | 1 September 2025 |
| Primary completion | 1 April 2026 |
| Estimated completion | 12 May 2026 |
Drugs / interventions tested
- Flaxseed — full drug profile →
- Diet
Conditions studied
- Type 2 Diabetes Mellitus (T2DM) — all drugs for Type 2 Diabetes Mellitus (T2DM) →
Sponsor
Ondokuz Mayıs University
Who can join
Adults 19 to 65, any sex, with Type 2 Diabetes Mellitus (T2DM). Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Evaluation of the effect of flaxseed on fasting blood glucose (mg/dL)
Time frame: From enrollment to the end of intervention at 12 weeks -
Evaluation of the effect of flaxseed on HbA1c (%)
Time frame: From enrollment to the end of intervention at 12 weeks -
Evaluation of the effect of flaxseed on total triglyceride (mg/dL)
Time frame: From enrollment to the end of intervention at 12 weeks -
Evaluation of the effect of flaxseed on total cholesterol (mg/dL)
Time frame: From enrollment to the end of intervention at 12 weeks -
Evaluation of the effect of flaxseed on HDL-cholesterol (mg/dL)
Time frame: From enrollment to the end of intervention at 12 weeks -
Evaluation of the effect of flaxseed on LDL-cholesterol (mg/dL)
Time frame: From enrollment to the end of intervention at 12 weeks
Sponsor's own description
The main goal of this clinical trial is to determine the effect of flaxseed added to the diet on biochemical parameters and quality of life in patients with Type 2 diabetes mellitus (T2DM). The main questions it aims to answer are: * Does flaxseed supplementation given to T2DM patients for 12 weeks have an effect on biochemical parameters? * Does flaxseed supplementation given to T2DM patients for 12 weeks have an effect on quality of life? Researchers will compare patients with T2DM consume diet added flaxseed to a control group to see if flaxseed effect on biochemical parameters and quality of life. Participants will: * Complete the questionnaire, record the 3-day food consumption and be taken the anthropometric measurements at the beginning and end of the study. * Take diet added 30 g ground flaxseed (intervention group) or only diet (control group) every day for 12 weeks. * Visit the clinic once every 4 weeks for follow-up. * Report the dietary adherence and gastrointestinal symptoms on a phone call once every week.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06911060
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Flaxseed
Trials testing the same drug.
- NCT07530965 — OMEGA-3-FATTY ACIDS IN CHILDREN WITH SICKLE CELL DISEASE · NA · not yet recruiting
- NCT05245825 — Flaxseed Supplementation in Prediabetic Adults (LINAPRED) · NA · unknown
- NCT03915600 — Efect of Quinoa and Flaxseed in Cititoxicity and Glicemic Control in Metabolic Syndrome Patients · NA · unknown
- NCT04024605 — Bioavailability of Protein and Amino Acids From Oilseeds in Healthy Volunteers · NA · unknown
- NCT03183102 — The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator. · NA · completed
Other recruiting trials for Type 2 Diabetes Mellitus (T2DM)
Currently open trials in the same condition.
- NCT07533539 — Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration · Phase 1 · recruiting
- NCT07366775 — A Telenursing Program to Support Diabetes Self-Management · NA · active not recruiting
- NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
- NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
- NCT07442006 — Glycemic Variability of Combination Therapies in T2DM · Phase 4 · recruiting
Other Ondokuz Mayıs University trials
Trials by the same sponsor.
- NCT07500389 — Postural Habits, Body Awareness, and Functional Performance Across BMI Categories in Women · not yet recruiting
- NCT07535242 — Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS · not yet recruiting
- NCT07504848 — Stroke Mobility and Caregiver Outcomes · not yet recruiting
- NCT07525557 — Kinesiophobia, Pain and Disability in Chronic Neck Pain · recruiting
- NCT07497802 — Mindfulness-Based Psychoeducation for Women With Gynecological Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06911060 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ondokuz Mayıs University
- Last refreshed: 9 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06911060.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing